Biotech / Clinical development
Sagimet doses first AURORA patient, but its October filing carries no results
The exhibit is an October investor deck: $257.6 million of cash at June 30 plus a $115 million September offering fund operations to mid-2029, and the 800-patient AURORA Phase 3 has begun dosing with topline data due in 2H 2027.